The medication may also affect or be affected by insulin, since growth hormone can influence blood sugar levels
Ghrelin Receptor (GHS-R1a) Selective Activation Ipamorelin acts as a highly selective agonist of the growth hormone secretagogue receptor (GHS-R1a), mimicking the natural hormone ghrelin without affecting other pituitary hormone secretion: Selective binding to GHS-R1a receptors without stimulating ACTH, cortisol, or prolactin release Rapid onset of growth hormone pulse generation (peak levels within 40-60 minutes) No significant effect on appetite stimulation unlike other ghrelin mimetics Preserved feedback regulation through endogenous growth hormone-releasing inhibitory mechanisms Research indicates that ipamorelin releases growth hormone with potency and efficacy similar to GHRP-6 (EC50 approximately 1.3 nmol/L) but with superior selectivity for growth hormone secretion
This approach works with your body's existing physiological pathways, potentially offering a safer long-term strategy with fewer risks compared to exogenous HGH
View Protocol Complete dosage protocol and reconstitution guide for Selank Dosage (5 mg Vial) Protocol
Reported benefits (per available research): Studied in animal (rodent) models for tendon, ligament, and muscle healing, with researchers attributing effects to promotion of angiogenesis and fibroblast activity (preclinical studies from a Croatian research group at the University of Zagreb, spanning several decades) Originally investigated for gastroprotective properties
